Shuttle Pharmaceuticals Holdings, Inc.SHPHEarnings & Financial Report
Shuttle Pharmaceuticals Holdings, Inc. is a US-based clinical-stage biopharmaceutical company focused on developing novel radioprotective therapies and cancer supportive care products. It primarily operates in the oncology care segment, targeting unmet medical needs to reduce side effects of radiation therapy for cancer patients, and collaborates with clinical research partners to advance its late-stage product pipeline.
Revenue
$19.3K
Gross Profit
N/A
Operating Profit
$-1.5M
Net Profit
$-2.2M
Gross Margin
N/A
Operating Margin
-7607.0%
Net Margin
-11337.4%
YoY Growth
N/A
EPS
$-1.23
Shuttle Pharmaceuticals Holdings, Inc. Q2 FY2023 Financial Summary
Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $19.3K for Q2 FY2023, with a net profit of $-2.2M (-11337.4% margin).
Key Financial Metrics
| Total Revenue | $19.3K |
|---|---|
| Net Profit | $-2.2M |
| Gross Margin | N/A |
| Operating Margin | -7607.0% |
| Report Period | Q2 FY2023 |
Shuttle Pharmaceuticals Holdings, Inc. Annual Revenue by Year
Shuttle Pharmaceuticals Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $100.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $100.0K |
Shuttle Pharmaceuticals Holdings, Inc. Quarterly Revenue & Net Profit History
Shuttle Pharmaceuticals Holdings, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $22.0K | +14.0% | $-2.0M | -9249.6% |
| Q1 FY2024 | $13.7K | -18.2% | $-1.7M | -12680.6% |
| Q4 FY2023 | $43.3K | — | $-1.6M | -3790.4% |
| Q3 FY2023 | $20.8K | — | $-1.8M | -8633.5% |
| Q2 FY2023 | $19.3K | — | $-2.2M | -11337.4% |
| Q1 FY2023 | $16.7K | — | $-975.1K | -5843.1% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $16688 | $19267 | $20765 | $43280 | $13651 | $21960 |
| YoY Growth | N/A | N/A | N/A | N/A | -18.2% | 14.0% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|
| Assets | $10.4M | $8.8M | $7.4M | $6.0M | $4.8M | $2.8M |
| Liabilities | $3.5M | $1.9M | $1.8M | $1.9M | $2.0M | $2.0M |
| Equity | $6.9M | $6.9M | $5.6M | $4.1M | $2.8M | $801434 |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|
| Operating CF | $-1.3M | $-1.6M | $-1.5M | $-1.1M | $-1.2M | $-1.4M |